Navigation Links
Isolagen to Present at the JMP Securities Healthcare Focus Conference
Date:10/3/2008

EXTON, Pa., Oct. 3 /PRNewswire-FirstCall/ -- Isolagen, Inc. (Amex: ILE) announced today that Declan Daly, Chief Executive Officer, will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 3:30 p.m. (EST) at Le Parker Meridien hotel in New York, New York.

The presentation will be webcast live and can be accessed on the Isolagen website, http://www.isolagen.com, on the investors page. A replay will be available approximately three hours after the presentation and will be archived on the company's website for 90 days.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in Item 1A. "Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
2. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
3. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
5. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
6. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. ViroPharma to Present at Three October Healthcare Conferences
10. BioCryst to Present at the JMP Healthcare Focus Conference
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Cambridge Semantics ... that its Anzo Smart Data Lake® (Anzo SDL) product won ‘Best Text ... (SIIA) CODiE Awards. , Cambridge Semantics’ Anzo SDL uses Knowledge Graphs based ...
(Date:7/26/2017)... ... July 25, 2017 , ... The leading Regenerative Veterinary ... stem cell therapy has been used on more than 13,000 animals. VetStem ... potentially fatal injuries to tendons and ligaments. , In 2003 VetStem signed a ...
(Date:7/26/2017)... ... 26, 2017 , ... NLP Logix today announced a collaboration ... by Mayo Clinic and the experience in developing and deploying artificial intelligence solutions ... Microsoft Azure platform and will focus on assisting physicians to more accurately and ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Fiberstar, Inc ... and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is used to improve ... extend real tomato in sauces, condiments and spreads. Today, more than ever, consumers connect ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):